John Milne MP: speeches

Speeches

• 14 Sept 2026 · Water Sector: Public Ownership · Hansard source

  More

  It is a pleasure to serve under your chairship, Mrs Barker. Sometimes public ownership is best, and sometimes private is; I have no ideological view either way, but when it comes to the water industry, privatisation has been nothing short of disastrous. The main reason is inadequate regulation. In their blind assault on quangos and the civil service, which continues to this day, the Conservatives cut funding for the regulator so badly that it entirely lost the ability to do its job. No one noticed all the sewage going into our waterways, because there was no one left to look. Left to their own devices, water company bosses responded by extracting billions from the industry in excess profits while allowing the fabric of the system to slowly rot. It has all been exposed now and we know the sorry truth, but however angry we feel, in most cases that money cannot be recovered because the original investors sold out long ago. In my area of Horsham in West Sussex, Southern Water was one of the worst offenders. Things were so bad that the former CEO Matthew Wright now faces criminal charges for presiding over fraudulent sewage data. Painful as it is, we are now obliged to pay for the same infrastructure investment all over again through higher bills.

• 9 Jul 2026 · Lobular Breast Cancer: Moon Shot Project · Hansard source

  More

  I thank the hon. Member for his contribution and I very much agree. I also note that the right hon. Member for Makerfield (Andy Burnham), who is potentially our next Prime Minister, comes from Manchester, has visited the clinic and is already familiar with the campaign, so I am hopeful. As I was saying, lobular breast cancer is the sixth most prevalent cancer in women. That puts it ahead of melanoma cancer, ovarian cancer, brain cancer, kidney cancer and pancreatic cancer combined. Incredibly, there is still no specific treatment. Breast cancer as a whole costs this country over £3 billion a year. It takes around 11,200 lives annually, or the lives of roughly 31 women a day. Many of these are lobular cases, yet lobular breast cancer receives none of the targeted treatment that drives down mortality for other forms of this disease. Every woman who is diagnosed with lobular breast cancer is given the same drugs, the same protocols and the same guidelines as someone with an entirely different cancer. That is because the basic biology of lobular has never been established. It is this gap that the Lobular Moon Shot Project exists to close. We need £20 million over five years, which is just £4 million a year to crack the biology of this disease. That is not speculative research; it is a certain outcome. Other researchers in the UK and around the world can then take things forward to find targeted treatments, because this is a world problem and the world can find the solutions. Of course, there are many demands on Government funding and the national budget is always under pressure, but I think we would be hard pushed to find another project with such a relatively small need for such a big reward. This is a precise unfunded gap, and we already have a delivery partner in the shape of the Manchester Breast Centre, which is ready to begin this work. I will conclude by quoting Susan’s husband, Tristan, who is sitting behind me in the Gallery—it is strange that I have to speak these words rather than him, but that is the procedure of the House. He said: “The last overseas holiday Susan and I took together was to Easter Island, one of the most remote places on earth. Like so many people, I had always imagined the island’s famous stone statues—the moai—looking out across the Pacific Ocean. But when we arrived, we discovered something rather beautiful. Most of them face inland. We were told that they were positioned that way because they watch over their people rather than looking out to sea. Whether that is history, tradition or simply one interpretation, it touched us both deeply. Before we left, Susan found a beautifully carved wooden replica of one of the moai. We brought it home together, and today it sits in our house. Every time I look at it, I think of Susan. It reminds me that although she is no longer physically with me, her love, her courage and everything she stood for remain with me every single day. In my heart, I like to think she is still watching over me, just as those remarkable statues have watched over their people for generations. If Susan could stand in Westminster Hall today, she would not ask Members to remember her. She would instead ask you to remember the thousands of women diagnosed with invasive lobular breast cancer every year who still have no treatments designed specifically for their disease. That is why this debate matters. That is why the Lobular Moon Shot project matters. And that is why Susan’s legacy deserves not only our admiration, but our action. As Susan’s husband, I know she would have been deeply humbled that Members from every corner of this House have come together today to honour her life. She never sought recognition for herself. She simply wanted to leave the world a little safer, a little fairer and a little kinder than she found it. My sincere hope is that history will remember this debate not simply as a tribute to one remarkable woman, but as the day Parliament chose to transform admiration into action for future generations of women diagnosed with invasive lobular breast cancer. That would have been the greatest tribute we could ever have paid to Dr Susan Michaelis.”

• 9 Jul 2026 · Lobular Breast Cancer: Moon Shot Project · Hansard source

  More

  I beg to move, That this House has considered Government support for the Lobular Moon Shot Project. It is a pleasure to serve under your chairship, Mrs Hobhouse. MPs from across the House are here today to mark the anniversary of the death of my constituent Dr Susan Michaelis, founder of the Lobular Moon Shot Project. I thank the Backbench Business Committee for finding time at very short notice in the parliamentary schedule for this debate. Unfortunately, that short notice has prevented many MPs who would have liked to have spoken today from joining us. Unfortunately, that was a necessity. Today is a sad moment because Susan is no longer with us, but it is also a time to celebrate what she has achieved. Susan was a remarkable woman. She was warm but incredibly stoic. At no time was that clearer than on her last trip to Parliament in the summer of last year, oxygen tank in tow. Determined but evidently suffering, Susan stood for 22 minutes in a silent vigil outside No. 10 Downing Street with fellow campaigners and lobular ladies around her. We all understood that Susan was in her last days or weeks, so to watch her husband, campaigners and fellow lobular ladies rallying around her, literally supporting her, was a sight to behold. In her haste to deliver her petition to No. 10 that day, Susan had forgotten her ID. She was distraught. All that effort would be wasted, as the rules were clear: no ID, no entry. But that, of course, was not Susan’s way. Susan, with our support, blagged her way past security. Susan was never one to take no for an answer. Not long after, Susan died—just days after her meeting with the then Health Secretary. It might seem odd to say, given that I met Susan when she was already very ill with the lobular cancer that she was campaigning to prevent, but I feel that I met her in her prime. It was immediately clear to me that this was a person with an unparalleled commitment to her cause. Despite her illness, Susan never looked for the sympathy vote. She was always calm and matter of fact. She led by example. It is a reminder that her cause, while not yet complete, is a worthy one, and with a champion to match. Susan’s first campaign was in fact not lobular breast cancer; it was aviation safety. She flew commercial aircraft in the Australian outback, one of the few female pilots to take up this challenge, and piloted the first all-female crewed Qantas flight. This was before contaminated cabin air ended her flying career in 1997. She spent the following decades building the evidence base on aircraft cabin air contamination, with a PhD, an MSc, peer-reviewed research and a leading role in her home country’s Senate inquiry into cabin air quality. Her focus in her final years was on lobular breast cancer, and it is on this endeavour that I was pleased to support her as her local MP. Susan was diagnosed with invasive lobular breast cancer in 2013. It was a one millimetre mark—no lump, no pain. Two mammograms and two ultrasounds told her that there was nothing to worry about. An MRI scan found 2.5 cm and surgery then confirmed 7 cm. That gap between what standard imaging can see and what is actually there is the heart of why lobular breast cancer needs its own research programme. It behaves differently. It is missed because it is different and it is currently treated exactly the same as the most common form of the disease, because the underlying biology has never been properly funded. In May 2023, with her husband Tristan, Susan launched the Lobular Moon Shot Project in Horsham. She built it from nothing into a campaign that has cross-party support in this House, a partnership with the Manchester Breast Centre and a research plan costing £20 million over five years. In June 2025, Susan travelled to Manchester to help launch the scientific programme that she had spent years fighting for. It was a programme that, of course, she knew she would never benefit from herself. Nine days later, Susan died. She never received a reply from No. 10 and never got a chance to make her case to the then Health Secretary. So today, I will again make the case to the Government on behalf of Susan, the 22 patients a day who are diagnosed with lobular breast cancer, and the 463 MPs who have publicly supported her campaign so far, which I believe is the highest number of MPs to publicly support any individual campaign. Every day, 22 women in this country are told that they have lobular breast cancer—that is over 8,000 a year. This is not a rare disease; in fact, it is the sixth most prevalent cancer in women.